Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Polycystic kidney disease (PKD) is a genetic disorder causing cyst development in kidneys and other organs.
• Progressive cyst growth replaces normal kidney tissue, ultimately leading to kidney failure.
• Recent advancements in understanding PKD pathophysiology and genetics have opened new therapeutic avenues.

Purpose of the Study:

• To review the pathophysiologic patterns of autosomal dominant PKD.
• To summarize recent advances in the clinical pharmacotherapy for autosomal dominant PKD.
• To highlight a comprehensive treatment approach for slowing PKD progression.

Main Methods:

• Literature review of pathophysiologic mechanisms in PKD.
• Analysis of recent clinical trials and pharmacologic treatments for autosomal dominant PKD.
• Synthesis of information on nonpharmacologic interventions.

Main Results:

• Understanding PKD pathophysiology has enabled targeted treatments.
• Pharmacotherapies show promise in slowing the progression of certain PKD types.
• A combined pharmacologic and nonpharmacologic strategy can effectively manage PKD.

Conclusions:

• Targeting specific physiologic pathways offers a new strategy for PKD treatment.
• Multifaceted therapeutic approaches are crucial for managing autosomal dominant PKD.
• Slowing disease progression can delay the onset of kidney failure in PKD patients.